Cara Therapeutics, Inc. (CARA): Price and Financial Metrics

CARA POWR Grades

• CARA scores best on the Value dimension, with a Value rank ahead of 63.21% of US stocks.
• CARA's strongest trending metric is Quality; it's been moving down over the last 177 days.
• CARA ranks lowest in Stability; there it ranks in the 17th percentile.

CARA Stock Summary

• The ratio of debt to operating expenses for CARA THERAPEUTICS INC is higher than it is for about only 6.62% of US stocks.
• Over the past twelve months, CARA has reported earnings growth of -475.15%, putting it ahead of only 3.5% of US stocks in our set.
• As for revenue growth, note that CARA's revenue has grown -70.64% over the past 12 months; that beats the revenue growth of just 2.38% of US companies in our set.
• Stocks that are quantitatively similar to CARA, based on their financial statements, market capitalization, and price volatility, are PRTA, AEVA, CUE, CCCC, and ONCT.
• Visit CARA's SEC page to see the company's official filings. To visit the company's web site, go to www.caratherapeutics.com.

CARA Valuation Summary

• CARA's price/sales ratio is 16.1; this is 215.69% higher than that of the median Healthcare stock.
• Over the past 109 months, CARA's price/sales ratio has gone down 7.5.

Below are key valuation metrics over time for CARA.

CARA Growth Metrics

The 3 year cash and equivalents growth rate now stands at 45.55%.
• Its year over year net income to common stockholders growth rate is now at -762.03%.
• Its 5 year net income to common stockholders growth rate is now at -64.75%.

Over the past 33 months, CARA's revenue has gone up $19,541,000.

The table below shows CARA's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	39.427	-56.465	-88.517
2022-06-30	48.886	-45.389	-66.35
2022-03-31	25.883	-61.891	-92.889
2021-12-31	23.028	-60.087	-88.441
2021-09-30	134.296	23.246	23.85
2021-06-30	123.29	15.742	8.354

CARA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CARA has a Quality Grade of C, ranking ahead of 32.88% of graded US stocks.
• CARA's asset turnover comes in at 0.554 -- ranking 69th of 682 Pharmaceutical Products stocks.
• APLS, FENC, and FSTX are the stocks whose asset turnover ratios are most correlated with CARA.

The table below shows CARA's key quality metrics over time.